Abstract: The CD19-targeted chimeric antigen receptor (CAR) T-cell treatment has achieved clinical success in treating B-cell lineag hematopoietic malignancies. This accomplishment involved the precise and efficient elimination of tumor cells by tumor-associated antigen-redirected immune cells. As a result, the reinitiation of several CAR T-cell (CART) based clinical trials in solid tumors was promoed. However, developing a feasible and efficient CAR T based therapeutic modality for solid tumors is urgently needed given the diffeential properties between liquid and solid tumors. In this review, we discuss the advances in the management of cytotherapeutic modality for solid tumors. The aspects considered include toxicity management, target selection, and primer or conditioning treatment.